Mirum Pharmaceuticals (MIRM) News Today

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) shares rose on a raft of upbeat analyst actions and strong Q2 results.

• Positive Sentiment: Mirum joins the rank of stocks with Relative Strength ratings over 90, signaling strong technical momentum. Mirum Pharmaceuticals Joins Rank Of Stocks With RS Ratings Over 90
• Positive Sentiment: JMP Securities raises its price target to $81.00 and maintains a “market outperform” rating. Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $81.00
• Positive Sentiment: Evercore ISI boosts its price target from $77.00 to $89.00 with an “outperform” rating, implying roughly 48% upside. Evercore ISI price target raise via Benzinga
• Positive Sentiment: Raymond James Financial lifts its target from $77.00 to $82.00 and reiterates a “strong-buy” rating. Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $82.00 at Raymond James Financial
• Positive Sentiment: HC Wainwright ups its price objective to $80.00 and keeps a “buy” rating in place. HC Wainwright Boosts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $80.00
• Positive Sentiment: Mirum reports Q2 EPS of –$0.12 vs. –$0.31 expected and delivers revenue above forecasts, driving the stock to a new 52-week high. Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week High on Better-Than-Expected Earnings
• Positive Sentiment: Analysts at Zacks highlight the Q2 earnings and revenue beat, prompting them to raise their 2025 outlook. MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
• Positive Sentiment: Company updates FY2025 guidance, raising revenue expectations to $490–510 million versus the prior consensus of $448.6 million. (Company Update)
• Positive Sentiment: Full Q2 earnings call transcript confirms strong performance and business update. Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q2 2025 Earnings Call Transcript